Dr.Seigo Kinuya WFNMB2022 Congress Chair Professor, Department of Nuclear Medicine, Kanazawa University, Japan Interview by Dr.Francois Lamoureux You are the chair of the next congress of the world federation of nuclear medicine and biology (WFNMB) in kyoto japan 7-11 september 2022. could you give us an overview of the event. We are preparing to have […]
Read articleBy Grégoire Blais MD, FRCP Médecin nucléiste / Nuclear Medicine Specialist Centre de santé et de service sociaux de la Haute-Yamaska Granby, Québec, Canada Since March 2020 the significant « COVID-19 » pandemic has raged. From this period, there was significant confinement, social distancing and the wearing of masks were imposed. These measures have impacted on everyone’s […]
Read article
Sergio Calvo, President, Radiopharmaceuticals Division at Jubilant Pharma Interview by Dr.Francois Lamoureux Sergio, you are the president of the Radiopharmaceuticals Division of Jubilant Pharma. Can you give us a brief summary of your involvement in Nuclear Medicine and Jubilant? First, I would like to thank e-Patient for this opportunity. My background is in engineering and […]
Read articleDear friends and colleagues around the world Francois Lamoureux and I are thrilled to introduce to our international readers the new issue of the internationally acclaimed Nuclear Medicine magazine ePatient. The lack of concerted efforts in research and development of new radiopharmaceuticals in the last part of the 20th century created a climate of uncertainty […]
Read articleSince its foundation in 1884 as the “Montefiore Home for Chronic Invalids”, Montefiore Medical Center has grown into a large academic-based medical institution in New York City, spanning several teaching hospitals in the Bronx. It offers medical care in one of the most population-dense counties in the United States. Its Division of Nuclear Medicine has […]
Read articleClick here : CANM – Guidelines Document prepared by Drs. Alfonso Fasano, Ruban Gnanakumar, Heather Rigby, Andrew Ross, Jean-Paul Soucy, Alex Tamm -January 2020 In the investigation of movement disorders in which Dopamine transporter loss is a potential component, most commonly Parkinsonism, and there is diagnostic uncertainty, imaging with 123I-ioflupane can provide important information. […]
Read articleViruses, these deleterious mutants are constantly trying to attack us. They are stealthy and confusion The human cell consists of a nucleus that stores deoxyribonucleic acid or DNA. Messages from the nucleus of the cell to the different elements of the cell’s cytoplasm are conveyed by a vector – nucleic acid or RNA. These messages […]
Read articleDr. Lamoureux and I are pleased to introduce the new version of your acclaimed ePatient magazine. Who would have thought a year ago that there would be three articles on virus in a dedicated nuclear medicine magazine? This past ten month have been quite challenging for the entire globe population around the globe. Ass off […]
Read article“Do you know what the field of ‘Theranostics’ is?” I was a fourth-year medical student who had just submitted my Diagnostic Radiology residency applications. I had done all the things an applicant was supposed to do: lead the Radiology Interest Group, start a radiology medical education program for first year medical students, perform research, […]
Read articlePET/CT 作为当今分子影像最先进的诊断手段之一，在肿瘤早诊、分期、疗效评价及放疗定位等方面发挥着重要作用。新型核素探针的应用更为 PET 技术增加原动力。众多专家提及基于 PET/CT 的新技术、新方法，有望为肿瘤诊疗带来全新的突破，例如用核医学技术治疗泌尿系统肿瘤中的前列腺癌。 前列腺癌是老年男性常见的恶性肿瘤，且前列腺癌的生物学行为差异很大。因此，对于不同前列腺癌患者要进行个体化诊疗。其中，精准的影像学诊断、定位、分期是实现前列腺癌患者个体化诊疗的基石。 以往对于前列腺癌患者的影像学检查方法主要包括超声、核磁（MRI）以及骨扫描等，但上述检查均存在一定的局限性，例如无法有效地检出前列腺外的病灶，无法早期检出生化复发性前列腺癌患者的病灶等。 随着对前列腺特异性膜抗原（PSMA）研究的深入，研究者发现 PSMA 特异性表达于前列 腺上皮细胞，并在前列腺癌组织中高表达，尤其是转移性或去势抵抗性前列腺癌中，表达水平更高，这一特征使得 PSMA 可成为前列腺癌分子影像诊疗一体化的分子靶点。 目前，国际多项临床研究已经证实，PSMA PET/CT 对于诊断前列腺癌、评估病灶范围有重要价值，且在患者生化复发早期，甚至血 PSA 水平很低且其他影像检查手段均无阳性发现时，即可辅助检测出病灶，修正了近40%～60%的患者临床治疗方案的制定。 由于 PSMA PET/CT 显像优异的诊断效能，该检测方法目前已被国内外指南或专家共识所推荐。更重要的是，对于一线化疗失败等去势抵抗性前列腺癌患者，若经 PSMA PET/CT 显像证实其病灶高表达 PSMA，还可通过治疗药物 177Lu-PSMA 进行放射性核素治疗，对前列腺原发及转移病灶进行“精准定向打击”，实现“所治即所见”。 目前，该种核素靶向治疗转移性去势抵抗性前列腺癌患者的有效性以及安全性已得到临床研究充分印证，将有可能成为改善前列腺癌患者预后、延长其生存期的新兴方法和有力“武器”。
Read article
